Progyny 3rd Quarter 2026 Earnings Conference Call - PROGYNY INC

Explicit Guidance:

• Full-Year 2026 Revenue: Raised midpoint; projected range of $1.365 billion to $1.385 billion, reflecting organic growth of 5.9% to 7.5% (or 10.1% to 11.7% excluding $48.5 million in revenue from a client under transition of care).
• Full-Year 2026 Profitability: Expected Adjusted EBITDA of $235 million to $240 million; Net Income of $107 million to $110.6 million.
• Full-Year 2026 EPS: Projected earnings per diluted share of $1.30 to $1.35; Adjusted EPS of $2.09 to $2.13 (based on ~82 million fully diluted shares).
• Q4 2026 Revenue: Expected range of $344.7 million to $364.6 million, representing growth of 8.3% to 14.6%.
• Q4 2026 Profitability: Expected Adjusted EBITDA of $57.9 million to $62.9 million; Net Income of $28.5 million to $32.1 million.
• Q4 2026 EPS: Projected earnings per diluted share of $0.36 to $0.41; Adjusted EPS of $0.53 to $0.58 (based on 79 million fully diluted shares).

Business-Segment Outlook:

• Client & Lives Growth (2027): Anticipates having >660 clients representing 8.3 million covered lives once the new cohort is fully live in 2027.
• Launch Timing: ~100,000 lives added in the most recent season to launch in Q1 2027; a "meaningful number" of several hundred thousand expected to launch mid-year 2027; a small number already active in 2026.
• Client Mix: New cohort is diverse (universities, tech, banking, public health funds), ranging from 1,000 to >100,000 lives per client, with no single client making an outsized contribution.
• Retention & Expansion: Achieved near 100% retention of the existing base; approximately 20% of the base has committed to expanding services (consolidating women's health) for 2027.
• Product Attach Rates: ~100% attach rate for the pharmacy (Progeny Rx) program among new clients; expects 95–96% overall RX attach rate for 2027; over 3 million lives projected to utilize expanded products beyond RX starting in 2027.
• Progeny Select: First-year results were immaterial; focus remains on infrastructure build-out. Expected to become a key part of long-term growth as it scales.
• Utilization: Member engagement and utilization remain within long-established ranges; Q3 saw slightly higher utilization but reverted to fall patterns; Q4 visibility is strong with typical October/November seasonality.

Market and Competitive Outlook:

• Market Rationalization: Observing "signs of rationalization" as non-profitable or unscalable competitors exit or significantly scale back (one company exited a year ago; another is "pairing back").
• Competitive Landscape: Momentum driven by differentiation in outcomes and cost control rather than competitive takeaways, though some conversions from competitors (including a major large employer) did occur.
• Demand Drivers: Sustained demand attributed to high prevalence of infertility (1 in 5), employer cost pressures, and the need for comprehensive management of costly medical needs.
• Pricing/Margins: Gross margins expanded 130 basis points YoY due to stock comp reduction and care management efficiencies; management expects to taper investments in 2027, potentially allowing incremental gross profit to flow to EBITDA.
• Sales Pipeline: Entering 2027 with the strongest pipeline in company history, including a significant number of "jumbo" accounts and active opportunities.

Macro / Industry Outlook:

• Economic Environment: Market momentum is not isolated to one industry or geography, reflecting broad economic diversity.
• Medical Cost Inflation: Acknowledges continued high medical cost inflation and rising medical trends (e.g., GLP-1s); notes that despite this, employers are prioritizing fertility benefits due to prevalence and cost control needs.
• Regulatory/Social Trends: High demand driven by the "millennial workforce" demographic and employer focus on "family building and women's health" as top HR priorities.
• FX/Interest Rates: No specific commentary provided regarding FX or interest rate impacts on the outlook.

Strategic Initiatives:

• Partnerships: Relationship with Cigna (national partner) and regional plans is a key growth driver; first season yielded positive activity, with no new learnings identified that drastically alter the model.
• Technology/Data: Goal to secure eligibility files for >50% of lives by year-end 2026.
• Investment Strategy: Expects to taper back investment levels throughout 2027 after recent high investment cycles, aiming to return to incremental margin expansion.
• Capital Allocation: Share Repurchases: ~3 million shares purchased in Q3 for ~$83 million; ~$51 million remaining under the $200 million authorization; cumulative ~14 million shares bought since Nov 2023 (reducing shares outstanding by ~15%).
• Capex: Remains modest at ~2% of revenue ($9M ahead of 2025 spend YTD).

Risks and Headwinds to Outlook:

• Utilization Variability: Actual utilization and "ART cycle intensity" in 2027 remain variables; guidance for 2027 will be set in February based on early-year utilization data.
• Pipeline Execution: Success depends on the conversion of the large pipeline and timing of client launches (mid-year vs. Q1).
• Competitive Response: While market is rationalizing, competition remains active; large employer account decisions (e.g., the specific large employer facing challenges) are not relied upon exclusively.
• Assumption Risks: Guidance assumes member engagement remains consistent with historical patterns and that the "healthy" engagement observed in Q3 continues into Q4.
• Stock-Based Compensation: Future results may be impacted by the timing of expensing grants rolling off in 2026 and 2027.

Management Tone on the Future:

• Confidence: High confidence in long-term growth trajectory; CEO describes the setup for 2027 as "strongest ever" with "most diverse client base ever."
• Guidance Direction: Active raise of full-year 2026 midpoints based on strong Q3 results and healthy Q4 engagement expectations.
• Strategic Shift: Transitioning from heavy investment mode to a phase where marginal returns from cost containment and efficiencies will increasingly flow to the bottom line as 2027 investment tapering begins.
• Differentiation: Repeated emphasis on "proven solution," "cost control," and "outcomes" as the primary drivers of demand amidst a challenging macro environment.

Miscellaneous:

• Share Count: Fully diluted share counts used for guidance are approx. 82 million (Full Year 2026) and 79 million (Q4 2026).
• Cash Flow: Operating cash flow conversion to Adjusted EBITDA remains robust at >75%; $56 million generated in Q3; $207 million trailing 12-month.
• Balance Sheet: $196 million in cash/marketable securities; no debt; $200 million revolver available with no borrowings.
• DSO: Improved to just under 66 days (7 days lower than prior year); management believes nearing "maximum yield" due to reliance on health plan claim processing.